四川路橋(600039.SH):路橋集團參投的金堂縣新型城鎮化綜合試驗區PPP建設項目擬終止
格隆匯12月22日丨四川路橋(600039.SH)公佈,公司於2021年12月22日召開了第七屆董事會第四十七次會議,會議審議通過了《關於路橋集團解除金堂縣新型城鎮化綜合試驗區建設項目政府和社會資本合作(PPP)合同的議案》,同意路橋集團簽署《金堂縣新型城鎮化綜合試驗區建設項目政府和社會資本合作(PPP)合同解除協議》。
由於該項目未進入財政部PPP項目庫,融資受阻,導致項目無法實施推進。經多方協商一致,擬解除該項目合同。截止2020年2月20日,天府水城公司在該項目中實際發生投資約為11.25億元,應收款14.50億元。項目合同解除後,天府水城公司將依法清算後予以註銷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.